Activity Overview
Ovarian cancer remains one of the most lethal gynecologic malignancies, with high recurrence rates and frequent progression to platinum-resistant disease. Although advances such as PARP inhibitors, antibody-drug conjugates, and immunotherapy have expanded treatment options, clinicians continue to face challenges in biomarker testing, treatment sequencing, and the management of therapy-related toxicities. To address these gaps, this program uses an interactive, case-based symposium format to review key clinical trial data and their application in practice.
This educational activity is an archive of the live presentation held in conjunction with the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer on April 13, 2026, in San Juan, Puerto Rico.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, radiation oncologists, pathologists, OB/GYNs, advanced practice providers, nurses, pharmacists, trainees, and other health care providers involved in the management of patients with ovarian cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe germline and somatic testing strategies to guide treatment approaches in patients with ovarian cancer
- Characterize the mechanistic rationale of emerging novel therapeutic strategies for the treatment of ovarian cancer
- Integrate recent clinical trial evidence into individual treatment plans for patients with ovarian cancer
- Develop effective strategies to monitor for, identify, and manage adverse effects associated with novel therapies in patients treated for ovarian cancer
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here